Executive Summary
Neimeth International Pharmaceuticals Plc is seeking shareholder approval for a N1.98 billion capital restructuring to improve its balance sheet and future dividend capacity. The company plans to transfer N1.99 billion from its share premium account to its revenue reserve to offset accumulated losses. This move aims to eliminate or significantly reduce its retained deficit and restore distributable reserves, positioning the company to pay dividends in the future. The restructuring requires shareholder consent and court sanction, with a virtual meeting scheduled for March 31, 2026, for shareholders to vote on the proposal. The long-term implications could be meaningful, improving how the company’s financial position is perceived by lenders and institutional investors.
- Neimeth restructures N1.98bn to improve finances and future dividends, pending shareholder and court approval.
What Is Driving The Story?
- Accumulated losses
- Improve balance sheet